Skip to main content
. 2018 Jun 22;12(10):1249–1254. doi: 10.1093/ecco-jcc/jjy087

Figure 1.

Figure 1.

Fistula closure rates [a] and fistula improvement rates [b] with adalimumab treatment from Week 12 to Week 292 in IMAgINE 1 and IMAgINE 2 in patients with fistulae at baseline (non-responder imputation [NRI] in IMAgINE1, hybrid non-responder imputation [hNRI] in IMAgINE2 and as-observed analyses).